{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:08:48Z","timestamp":1784070528345,"version":"3.55.0"},"reference-count":83,"publisher":"Georg Thieme Verlag KG","issue":"06","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Predicting future advances in science is practically impossible because unexpected discoveries can radically change the march of ongoing processes. Predicting the nearest future may have a slightly greater chance of success. First, the diagnosis of risk factors for Alzheimer's disease (AD), based on the preponderant role of genetics, will be made very early. Diagnosis will be made with biomarkers prior to clinical manifestations. Furthermore, the prevention of AD and of dementia due to AD will be possible with better control of the many risk factors for dementia, healthier lifestyles, multi-target drugs, and genetic therapy. The relationship between AD and aging will be better understood, opening possibilities for intervention in aging itself. As the pathophysiology of AD is not unique, treatment will be individualized, according to the stage and characteristics of the disease. Most clinical trials will have surrogate markers as primary outcomes. Treatments to decrease the velocity or arrest the evolution of mild cognitive impairment (MCI) and mild dementia caused by AD will be available. Additionally, artificial intelligence (AI) will aid in the diagnosis and selection of the best treatments. Access to the new methods for diagnosing and treating AD is currently limited to a small parcel of the population, especially in low- and middle-income countries, because of their high costs. Due to the high prevalence of AD, it is possible these will become less expensive in the future. The possibility of reversing dementia once it has set in will probably have to wait for longer.<\/jats:p>","DOI":"10.1055\/s-0046-1824435","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:58:40Z","timestamp":1784069920000},"page":"001-010","source":"Crossref","is-referenced-by-count":0,"title":["The past, present, and future of Alzheimer's disease\u2014part 3: the future"],"prefix":"10.1055","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5721-1525","authenticated-orcid":false,"given":"Ricardo","family":"Nitrini","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Departamento de Neurologia, Grupo de Neurologia Cognitiva e Comportamental, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-9253","authenticated-orcid":false,"given":"Leonel Tadao","family":"Takada","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Departamento de Neurologia, Grupo de Neurologia Cognitiva e Comportamental, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8303-6732","authenticated-orcid":false,"given":"Sonia Maria Dozzi","family":"Brucki","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Departamento de Neurologia, Grupo de Neurologia Cognitiva e Comportamental, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"issue":"07","key":"ref1","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1056\/NEJMc2109455","article-title":"Donanemab in early Alzheimer's disease","volume":"385","author":"A J Espay","year":"2021","journal-title":"N Engl J Med"},{"issue":"05","key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0045-1807718","article-title":"Amyloid immunotherapy for Alzheimer's disease: the case for cautious adoption","volume":"83","author":"J M Schott","year":"2025","journal-title":"Arq Neuropsiquiatr"},{"issue":"08","key":"ref3","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"C R Jack Jr","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"12","key":"ref4","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","article-title":"Alzheimer disease as a clinical-biological construct \u2013 an international working group recommendation","volume":"81","author":"B Dubois","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e2024E001","DOI":"10.1590\/1980-5764-DN-2024-E001","article-title":"What is \u201cbiological Alzheimer's disease\u201d?","volume":"18","author":"R Nitrini","year":"2024","journal-title":"Dement Neuropsychol"},{"issue":"08","key":"ref6","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1111\/jgs.18902","article-title":"Montreal Cognitive Assessment (MoCA) XpressO: Validation of a digital self-administered cognitive prescreening tool","volume":"72","author":"S Klil-Drori","year":"2024","journal-title":"J Am Geriatr Soc"},{"issue":"01","key":"ref7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41746-024-01347-7","article-title":"Detecting early cognitive deficits in preclinical Alzheimer's disease using a remote digital multi-day learning paradigm","volume":"8","author":"R J Jutten","year":"2025","journal-title":"NPJ Digit Med"},{"issue":"04","key":"ref8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/alz.12422","article-title":"Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease","volume":"18","author":"D P Veitch","year":"2022","journal-title":"Alzheimers Dement"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"796129","DOI":"10.3389\/fnins.2022.796129","article-title":"Imaging synaptic density: the next Holy Grail of neuroscience?","volume":"16","author":"M E Serrano","year":"2022","journal-title":"Front Neurosci"},{"issue":"03","key":"ref10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/s0896-6273(00)81109-5","article-title":"Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles","volume":"24","author":"M M Mesulam","year":"1999","journal-title":"Neuron"},{"issue":"04","key":"ref11","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","article-title":"Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment","volume":"30","author":"R D Terry","year":"1991","journal-title":"Ann Neurol"},{"issue":"01","key":"ref12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41380-024-02656-9","article-title":"PET imaging of neuroinflammation: any credible alternatives to TSPO yet?","volume":"30","author":"F Chauveau","year":"2025","journal-title":"Mol Psychiatry"},{"issue":"06","key":"ref13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/bpa.12719","article-title":"Neuropathological lesions in the very old: results from a large Brazilian autopsy study","volume":"29","author":"C K Suemoto","year":"2019","journal-title":"Brain Pathol"},{"issue":"S 02","key":"ref14","doi-asserted-by":"publisher","first-page":"e104467","DOI":"10.1002\/alz70856_104467","article-title":"The use of portable MRI in the detection and monitoring of amyloid-related imaging abnormalities","volume":"21","author":"K J Sharifi","year":"2025","journal-title":"Alzheimer's Dement"},{"issue":"06","key":"ref16","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease","volume":"31","author":"K Horie","year":"2025","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"102642","DOI":"10.1016\/j.arr.2024.102642","article-title":"Biomarkers of synaptic degeneration in Alzheimer's disease","volume":"104","author":"Q Cheng","year":"2025","journal-title":"Ageing Res Rev"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"J A Hardy","year":"1992","journal-title":"Science"},{"issue":"01","key":"ref19","doi-asserted-by":"publisher","first-page":"e200224","DOI":"10.1212\/NXG.0000000000200224","article-title":"The Spectrum of Genetic Risk in Alzheimer Disease","volume":"11","author":"N Karagas","year":"2025","journal-title":"Neurol Genet"},{"issue":"05","key":"ref20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41582-023-00789-z","article-title":"A global view of the genetic basis of Alzheimer disease","volume":"19","author":"C Reitz","year":"2023","journal-title":"Nat Rev Neurol"},{"issue":"03","key":"ref21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.neurobiolaging.2010.03.025","article-title":"The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE","volume":"33","author":"R J Guerreiro","year":"2012","journal-title":"Neurobiol Aging"},{"issue":"06","key":"ref22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jalz.2016.01.012","article-title":"Molecular genetics of early-onset Alzheimer's disease revisited","volume":"12","author":"R Cacace","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"01","key":"ref23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","article-title":"Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study","volume":"11","author":"E M Reiman","year":"2020","journal-title":"Nat Commun"},{"issue":"05","key":"ref24","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","article-title":"APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease","volume":"30","author":"J Fortea","year":"2024","journal-title":"Nat Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-024-07185-7","article-title":"APOE4\/4 is linked to damaging lipid droplets in Alzheimer's disease microglia","volume":"628","author":"M S Haney","year":"2024","journal-title":"Nature"},{"issue":"03","key":"ref26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41582-025-01062-1","article-title":"The impact of rare genetic variants on Alzheimer disease","volume":"21","author":"L De Deyn","year":"2025","journal-title":"Nat Rev Neurol"},{"issue":"07","key":"ref27","doi-asserted-by":"publisher","first-page":"e70148","DOI":"10.1111\/jnc.70148","article-title":"Milestone Review: The History of Molecular Genetics Analysis of Alzheimer's Disease","volume":"169","author":"J Hardy","year":"2025","journal-title":"J Neurochem"},{"issue":"02","key":"ref28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer's disease","volume":"368","author":"R Guerreiro","year":"2013","journal-title":"N Engl J Med"},{"issue":"02","key":"ref29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.12779\/dnd.2025.24.2.75","article-title":"Protective Genes Against Alzheimer's Disease: Case Review and Therapeutic Implications","volume":"24","author":"N Hossain","year":"2025","journal-title":"Dement Neurocognitive Disord"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer's disease and age-related cognitive decline","volume":"488","author":"T Jonsson","year":"2012","journal-title":"Nature"},{"issue":"12","key":"ref31","doi-asserted-by":"publisher","first-page":"e0237122","DOI":"10.1371\/journal.pone.0237122","article-title":"The protective mutation A673T in amyloid precursor protein gene decreases A\u03b2 peptides production for 14 forms of Familial Alzheimer's Disease in SH-SY5Y cells","volume":"15","author":"A Guyon","year":"2020","journal-title":"PLoS One"},{"issue":"11","key":"ref32","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","article-title":"Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report","volume":"25","author":"J F Arboleda-Velasquez","year":"2019","journal-title":"Nat Med"},{"issue":"04","key":"ref33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The Cellular Phase of Alzheimer's Disease","volume":"164","author":"B De Strooper","year":"2016","journal-title":"Cell"},{"issue":"09","key":"ref34","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/ng.3916","article-title":"Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease","volume":"49","author":"R Sims","year":"2017","journal-title":"Nat Genet"},{"issue":"04","key":"ref35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"M T Heneka","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1125982","DOI":"10.3389\/fphar.2023.1125982","article-title":"Microglia: A pharmacological target for the treatment of age-related cognitive decline and Alzheimer's disease","volume":"14","author":"C G McKee","year":"2023","journal-title":"Front Pharmacol"},{"issue":"05","key":"ref37","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/brain\/awae035","article-title":"Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles","volume":"147","author":"P S\u00e1nchez-Juan","year":"2024","journal-title":"Brain"},{"issue":"22","key":"ref38","doi-asserted-by":"publisher","first-page":"11941","DOI":"10.3390\/ijms252211941","article-title":"Neuroinflammatory Biomarkers in Alzheimer's Disease: From Pathophysiology to Clinical Implications","volume":"25","author":"F Roveta","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"09","key":"ref39","doi-asserted-by":"publisher","first-page":"e70648","DOI":"10.1002\/alz.70648","article-title":"Recent advances in neuroimaging of Alzheimer's disease and related dementias","volume":"21","author":"J Ottoy","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"01","key":"ref40","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40520-025-03112-6","article-title":"Clinical prediction models using artificial intelligence approaches in dementia","volume":"37","author":"N Veronese","year":"2025","journal-title":"Aging Clin Exp Res"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1101\/2025.09.30.678854","article-title":"A Systematic Fairness Evaluation of Racial Bias in Alzheimer's Disease Diagnosis Using Machine Learning Models","author":"N G Baddam","year":"2025","journal-title":"bioRxiv"},{"issue":"07","key":"ref42","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.neurobiolaging.2009.04.002","article-title":"Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease","volume":"30","author":"J L Price","year":"2009","journal-title":"Neurobiol Aging"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission","volume":"404","author":"G Livingston","year":"2024","journal-title":"Lancet"},{"issue":"06","key":"ref44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0044-1791755","article-title":"Alzheimer's disease: part 2 - the present","volume":"82","author":"R Nitrini","year":"2024","journal-title":"Arq Neuropsiquiatr"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial","volume":"385","author":"T Ngandu","year":"2015","journal-title":"Lancet"},{"issue":"08","key":"ref46","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jama.2025.12923","article-title":"Structured vs self-guided multidomain lifestyle interventions for global cognitive function: The US POINTER randomized clinical trial","volume":"334","author":"L D Baker","year":"2025","journal-title":"JAMA"},{"issue":"09","key":"ref47","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1002\/alz.13101","article-title":"Latin American Initiative for Lifestyle Intervention to Prevent Cognitive Decline (LatAm-FINGERS): Study design and harmonization","volume":"19","author":"L Crivelli","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"04","key":"ref48","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.trci.2017.09.002","article-title":"Speed of processing training results in lower risk of dementia","volume":"3","author":"J D Edwards","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"03","key":"ref49","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11065-021-09515-2","article-title":"A Game a Day Keeps Cognitive Decline Away? A Systematic Review and Meta-Analysis of Commercially-Available Brain Training Programs in Healthy and Cognitively Impaired Older Adults","volume":"32","author":"L Nguyen","year":"2022","journal-title":"Neuropsychol Rev"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/20552076251324015","article-title":"Feasibility and acceptability of a remote computerized cognitive training employing telehealth in older adults with subjective cognitive complaints","volume":"11","author":"M F Montesinos","year":"2025","journal-title":"Digit Health"},{"issue":"02","key":"ref51","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/gps.5421","article-title":"Cognitive stimulation therapy for people with dementia in Brazil (CST-Brasil): Results from a single blind randomized controlled trial","volume":"36","author":"V Marinho","year":"2021","journal-title":"Int J Geriatr Psychiatry"},{"issue":"12","key":"ref52","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1093\/brain\/awae292","article-title":"The emerging field of non-invasive brain stimulation in Alzheimer's disease","volume":"147","author":"G Koch","year":"2024","journal-title":"Brain"},{"issue":"05","key":"ref53","doi-asserted-by":"publisher","first-page":"100098","DOI":"10.1016\/j.tjpad.2025.100098","article-title":"Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities","volume":"12","author":"G B Frisoni","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"02","key":"ref54","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease","volume":"9","author":"S B Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"12","key":"ref55","doi-asserted-by":"publisher","first-page":"e70905","DOI":"10.1002\/alz.70905","article-title":"Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study","volume":"21","author":"C H Van Dyck","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"06","key":"ref56","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"J R Sims","year":"2023","journal-title":"JAMA"},{"issue":"02","key":"ref57","doi-asserted-by":"publisher","first-page":"e70098","DOI":"10.1002\/trc2.70098","article-title":"Alzheimer's disease drug development pipeline: 2025","volume":"11","author":"J L Cummings","year":"2025","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","article-title":"Drug development in Alzheimer's disease: the path to 2025","volume":"8","author":"J Cummings","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"01","key":"ref59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/jnnp-2023-331941","article-title":"Comparison of relative change with effect size metrics in Alzheimer's disease clinical trials","volume":"95","author":"T E Goldberg","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"e20230099","DOI":"10.1590\/1980-5764-DN-2023-0099","article-title":"Anti-amyloid therapies do not slow Alzheimer's disease progression","volume":"17","author":"M Kurkinen","year":"2024","journal-title":"Dement Neuropsychol"},{"issue":"05","key":"ref61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0045-1808082","article-title":"Monoclonal antibodies against beta-amyloid protein (lecanemab and donanemab) should not be used in the treatment of Alzheimer's disease","volume":"83","author":"R Nitrini","year":"2025","journal-title":"Arq Neuropsiquiatr"},{"issue":"04","key":"ref63","doi-asserted-by":"publisher","first-page":"620","DOI":"10.14283\/jpad.2023.103","article-title":"Geroscience and Alzheimer's disease drug development","volume":"10","author":"J Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"12","key":"ref64","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jama.2025.11289","article-title":"Geroscience: A Translational Review","volume":"334","author":"S B Kritchevsky","year":"2025","journal-title":"JAMA"},{"issue":"04","key":"ref65","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/XCE.0000000000000159","article-title":"Development of Clinical Trials to Extend Healthy Lifespan","volume":"7","author":"J N Justice","year":"2018","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"05","key":"ref66","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/joim.13141","article-title":"Senolytic drugs: from discovery to translation","volume":"288","author":"J L Kirkland","year":"2020","journal-title":"J Intern Med"},{"issue":"19","key":"ref68","doi-asserted-by":"publisher","first-page":"9748","DOI":"10.3390\/ijms26199748","article-title":"From Diabetes to Degenerative Diseases: The Multifaceted Action of Metformin","volume":"26","author":"L IM Campagnoli","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"22","key":"ref69","doi-asserted-by":"publisher","first-page":"6358","DOI":"10.1016\/j.cell.2024.08.021","article-title":"Metformin decelerates aging clock in male monkeys","volume":"187","author":"Y Yang","year":"2024","journal-title":"Cell"},{"issue":"06","key":"ref70","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cmet.2016.05.011","article-title":"Metformin as a Tool to Target Aging","volume":"23","author":"N Barzilai","year":"2016","journal-title":"Cell Metab"},{"issue":"01","key":"ref71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13195-023-01355-x","article-title":"A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol","volume":"16","author":"M Barbera","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"01","key":"ref72","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","article-title":"The probabilistic model of Alzheimer disease: the amyloid hypothesis revised","volume":"23","author":"G B Frisoni","year":"2022","journal-title":"Nat Rev Neurosci"},{"issue":"12","key":"ref74","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/s41593-023-01480-8","article-title":"The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation","volume":"26","author":"M R Nelson","year":"2023","journal-title":"Nat Neurosci"},{"issue":"03","key":"ref75","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/WAD.0000000000000680","article-title":"An Anti-tau therapeutic antibody Etalanetug (E2814): a phase 1, first-in-human (FIH) study of single and multiple ascending doses in healthy subjects","volume":"39","author":"S Rawal","year":"2025","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"12","key":"ref76","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","article-title":"Exploratory Tau biomarker results from a multiple ascending-dose study of BIIB080 in Alzheimer disease: a randomized clinical trial","volume":"80","author":"A L Edwards","year":"2023","journal-title":"JAMA Neurol"},{"issue":"01","key":"ref78","doi-asserted-by":"publisher","first-page":"7259","DOI":"10.1038\/s41467-024-50515-6","article-title":"The therapeutic implications of all-in-one AAV-delivered epigenome-editing platform in neurodegenerative disorders","volume":"15","author":"B Kantor","year":"2024","journal-title":"Nat Commun"},{"issue":"03","key":"ref79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46889\/JRMBR.2025\/6304","article-title":"Amyloid Precursor Protein (APP) A673T Mutation as a model for developing preventive strategies in Alzheimer's disease","volume":"6","author":"M Gonz\u00e1lez-Flores","year":"2025","journal-title":"J Reg Med Biol Res"},{"issue":"03","key":"ref80","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/cne.21744","article-title":"Tauopathy with paired helical filaments in an aged chimpanzee","volume":"509","author":"R F Rosen","year":"2008","journal-title":"J Comp Neurol"},{"issue":"01","key":"ref81","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1038\/s41598-024-56791-y","article-title":"Bearded capuchin monkeys as a model for Alzheimer's disease","volume":"14","author":"R D Rodriguez","year":"2024","journal-title":"Sci Rep"},{"issue":"05","key":"ref82","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jalz.2017.11.005","article-title":"The aged rhesus macaque manifests Braak stage III\/IV Alzheimer's-like pathology","volume":"14","author":"C D Paspalas","year":"2018","journal-title":"Alzheimers Dement"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1658074","DOI":"10.3389\/fncel.2025.1658074","article-title":"Human brain organoids: an innovative model for neurological disorder research and therapy","volume":"19","author":"H Li","year":"2025","journal-title":"Front Cell Neurosci"},{"issue":"08","key":"ref84","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1021\/acsmedchemlett.5c00299","article-title":"Discovery of a Small Molecule TREM2 Agonist with Improved In Vitro Pharmacokinetic Profile and Validated Target Engagement","volume":"16","author":"S Yuan","year":"2025","journal-title":"ACS Med Chem Lett"},{"issue":"04","key":"ref85","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1007\/s12035-024-04545-2","article-title":"Association between the gut microbiota and Alzheimer's disease: an update on signaling pathways and translational therapeutics","volume":"62","author":"R Kulkarni","year":"2025","journal-title":"Mol Neurobiol"},{"issue":"01","key":"ref86","doi-asserted-by":"publisher","first-page":"2261509","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the Brainshuttle\u2122 amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"H P Grimm","year":"2023","journal-title":"MAbs"},{"issue":"01","key":"ref87","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41746-024-01211-8","article-title":"Regulatory considerations for developing remote measurement technologies for Alzheimer's disease research","volume":"7","author":"G Erdemli","year":"2024","journal-title":"NPJ Digit Med"},{"issue":"04","key":"ref88","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41582-024-00940-4","article-title":"Is Alzheimer disease a disease?","volume":"20","author":"A D Korczyn","year":"2024","journal-title":"Nat Rev Neurol"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0046-1824435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:58:45Z","timestamp":1784069925000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0046-1824435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":83,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2026,5,12]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["s00461824435"],"URL":"https:\/\/doi.org\/10.1055\/s-0046-1824435","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}